Linnich, Germany

Elke Janocha

This inventor holds 2 USPTO granted patents. Top assignee: Gruenenthal Gmbh. Active years: 2000-2010.


% Patents Active = 50.0

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2000-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Elke Janocha

Introduction

Elke Janocha is a prominent inventor based in Linnich, Germany. She has made significant contributions to the field of biochemistry, particularly in the development of methods and proteins that have important applications in medical science. With a total of 2 patents, her work continues to influence research and innovation.

Latest Patents

Among her latest patents, one includes a method of measuring the activation or deactivation of G(alpha)i- or G(alpha)o-coupled receptors. This patent also encompasses methods for identifying agonists or antagonists of such receptors. Another notable patent involves chimeric proteins that possess fibrinolytic and thrombin-inhibiting properties. These chimeric proteins are designed with a plasminogen-activating amino acid sequence linked at their C-terminal end to a thrombin-inhibiting amino acid sequence.

Career Highlights

Elke Janocha is currently associated with Grünenthal GmbH, a company known for its focus on innovative pain management solutions. Her work at this organization has allowed her to collaborate with other experts in the field, enhancing the impact of her inventions.

Collaborations

Some of her notable coworkers include Stephan Wnendt and Gerd J. Steffens. Their collaborative efforts contribute to the advancement of research and development in their respective areas of expertise.

Conclusion

Elke Janocha's innovative work and patents reflect her dedication to advancing medical science through biochemistry. Her contributions continue to pave the way for future discoveries and applications in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…